Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

ImClone/Bristol will discuss potential for submitting an sBLA for the indication with FDA.

You may also be interested in...



Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication

Approval marks the eighth indication for docetaxel in five different tumor types.

Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication

Approval marks the eighth indication for docetaxel in five different tumor types.

Bristol Boosts ImClone Funding To Accelerate Erbitux Development

Bristol will invest an additional “several hundred million dollars” toward Erbitux late-stage clinical trials in brain, breast, bladder, esophageal, gastric and lung cancers.

Related Content

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel